Dr. John Cush RheumNow
6 years 10 months ago
The draft 2020 ACR #gout guidelines were presented at the last slot of the meeting. Big changes for ULT initiation #ACR19 @philipcrobinson [Slides attached] https://t.co/4g3YUlm7Sa
Few rheumatologic diseases have diagnostic criteria, so clinicians often rely on classification criteria to diagnose patients in clinic. Because classification criteria were not designed to be used for these purposes, they have important limitations.
At the 2019 ACR annual meeting, several abstracts looked at the importance of myopia (muscle wasting due to illness at any age) and sarcopenia (age related muscle wasting) in the setting of various rheumatologic diseases.
Dr. John Cush RheumNow
6 years 10 months ago
Long term results for GCA pts on TCZ (GiACTA): No new safety signals. Nearly 50% of those on TCZ QW maintained remission. Flares noted in PBO/ cessation TCZ and remission restored in majority once TCZ restarted. https://t.co/DN6TWYgWsH Plenary abs #808 #ACR19 @uptoTate
Monday was another full day of sessions and studies here in Atlanta. Following is my roundup of day two.The Safety of Methotrexate
Dr. John Cush RheumNow
6 years 10 months ago
99mTc-maraciclatide (which binds integrins) whole body imaging has similar uptake to PDUS evaluation for synovial inflammation. It is quick, and widely available. Cost may be prohibitive, however. Abstract #286 https://t.co/4LqrzcoA9U #ACR19 @uptoTate
Dr. John Cush RheumNow
6 years 10 months ago
ACR has released 3 FREE "SPOTLIGHT" Slide Decks on RA, SLE, SpA; ~15 slides each deck; compilations of cool abstracts presented at #ACR19. Use the link supplied below https://t.co/CsKVMDoGoL
Dr. John Cush RheumNow
6 years 10 months ago
FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT
Dr. John Cush RheumNow
6 years 10 months ago
abstr#0848 - Retrospective study Medicare database to evaluat outcomes of chronic low dose steroids (GCs) in Rheum Dz: n= 246,297, 47% on GCs. Pts on steroids have :
1. ⬆️ use of narcotics (pain)
2. RA
3. ⬆️hosp visits related to infx
4. Less f/u https://t.co/xD8isyKZsz
Dr. John Cush RheumNow
6 years 10 months ago
Plenary session shows AA/blacks at higher risk for #SLE & that blacks have 16 fold increased risk for IHD, CVD. CV risk accelerated at yrs 1 & 10. Copy & paste. #ACR19
Abst 805 https://t.co/pW8JdGxCUf https://t.co/lLPTnyTa2z
As we enter flu season it is of the utmost importance that we remember to assess our patients’ influenza vaccine status at each visit.
Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.
Dr. John Cush RheumNow
6 years 10 months ago
Abstr#1898 #acr19 @kDAO2011. Danish prospective RA registry of pregnancy & offspring n= 816 - kids of moms w/ RA performed a little worse in math grades 2,4,6, 8 compared to peers regardless of maternal seropositivity. No influence by paternal RA. https://t.co/bOBDtjVtfm
The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.
Panel Presentation: Psoriatic Arthritis
Drs. Eric Ruderman, Alexis Ogdie, Jessica Walsh, and Jose Scher discuss the giselkumab trials, where IL-23 inhibitors fit in practice, ixekizumab withdrawal, and more that presented at the 2019 ACR/ARP annual meeting in Atlanta.
